The results show that, compared with individuals who received only two doses five months prior, individuals who received three doses of the vaccine (7 days or more after the third dose) had 92 per cent lower risk of severe Covid-19 disease and 81 per cent lower risk of Covid-19-related death. 🍏 Pfizer-BioNTech’s COVID-19 Vaccine Third Dose More Effective in Reducing Severe Coronavirus Illness: Lancet.
Govt sharply cuts projected availability of COVID-19 vaccine doses by 81 cr for Aug-Dec
The Centre has revised the list and cut down the production expectations to 135 crore doses from five COVID-19 vaccines in an affidavit filed before the Supreme Court on June 26 The Centre revised down its May expectation of 216 COVID-19 vaccine production Joe C Mathew
Updated Jun 27, 2021, 4:26 PM IST
The Central government has brought down the production and availability estimates of COVID-19 vaccine in India during August-December 2021 from 216 crore doses to 135 crore in less than two months' time.
While the government had in a press conference on May 13 said the supply of eight different vaccines that are in various stages of development and production at that time can cumulatively account for 216 crore doses during the August-December period, it has revised the list and cut down the production expectations to 135 crore doses from five COVID-19 vaccines in an affidavit filed before the Supreme Court on June 26.
People previously infected with the novel coronavirus responded very strongly to one dose of the Pfizer vaccine, regardless of when they were infected and whether or not they had detectable antibodies against Covid-19 prior to receiving the vaccine, a new study suggests.